Modalities of use of oral propranolol in proliferative infantile hemangiomas: an international survey among practitioners.

Modalities of use of oral propranolol in proliferative infantile hemangiomas: an international survey among practitioners. Br J Dermatol. 2020 Mar 27;: Authors: Robert J, Tavernier E, Boccara O, Mashiah J, Mazereeuw-Hautier J, Maruani A Abstract Infantile hemangiomas (IHs) are common benign vascular tumours in infants (estimated prevalence 5% to 10%).1 Oral propranolol is currently the first-line treatment for complicated proliferative IHs.2 It is approved by the US Food and Drug Administration and the European Medicines Agency for treating complicated IHs, but questions remain regarding the optimal modalities of use.3 We conducted an international survey to assess practices in prescribing oral propranolol for IHs among practitioners dealing with IHs worldwide. PMID: 32221977 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research